Bernstein SocGen resumes Revvity stock coverage with Market Perform

Bernstein SocGen resumed coverage on Revvity with a Market Perform rating and a $115 price target, arguing the stock remains an AI loser in tools with a hard-to-change narrative over the next year. The article also notes Revvity beat Q1 2026 EPS expectations at $1.06 vs. $1.02 and revenue at $711 million vs. $704.67 million, but that positive earnings update is offset by valuation concerns and a lowered Stifel target to $100 from $110. Overall, the tone is cautious to mixed, with limited immediate market impact beyond the stock-specific analyst calls.

Analysis

The market is pricing RVTY less on near-term execution and more on a multi-year narrative risk: if AI compresses the number of experiments needed in preclinical workflows, screening-heavy tool vendors can see unit demand weaken before overall drug discovery budgets visibly rise. That creates a classic lag problem — revenue may hold up for quarters because pharma adoption is gradual, but multiples can de-rate quickly once investors believe a growth endpoint has shifted. The key second-order effect is that the real pressure may fall less on broad life-science tools demand and more on the highest-value workflow nodes where automation directly substitutes for repeated assay volume.

The counterpoint is that AI efficiency could expand the addressable market by making marginal projects economically viable, which would favor companies with broad installed bases and recurring consumables tied to more experiments overall. In that scenario, the winners are firms that can pivot from selling throughput to selling decision support, integration, or proprietary data layers; the losers are those whose economics depend on brute-force screening intensity. Revvity’s valuation is therefore being judged on narrative fragility, not just operating results, and that usually means the stock can stay cheap longer than fundamentals alone would justify.

Near term, the risk/reward is asymmetric around guidance and sell-side tone rather than one quarter of earnings. The catalyst path is clear: any evidence of slower booking trends in preclinical automation or softening in high-content screening replacement cycles would reinforce the AI-disruption thesis; conversely, proof that pharma is using AI to run more programs, not fewer screens, would force a narrative reset. Given the current setup, this looks like a lower-conviction long until the market sees either a valuation washout or a product mix shift toward software/data-enabled revenue streams.

Key Decisions for Investors

• Avoid initiating fresh long RVTY at current levels; wait for either a 10-15% de-rating or clearer evidence that AI is expanding, not cannibalizing, preclinical workflows. Risk/reward is unfavorable until the narrative resets.
• Pair trade: short RVTY / long a broader life-science tools name with less preclinical screening exposure over the next 1-2 quarters. This isolates the AI-disruption discount while reducing market beta.
• If already long RVTY, sell upside call spreads into any post-earnings strength; the stock likely trades on sentiment rather than fundamentals over the next 3-6 months, limiting near-term multiple expansion.
• Watch for guidance on high-content screening, instrument placements, and consumables run-rate; if any of these weaken sequentially, add to the short on a 1-2 month horizon.
• For a contrarian setup, consider a small starter long only if the stock sells off hard on narrative alone while results remain intact; use tight risk limits because the multiple can stay compressed for several quarters.